Showing posts with label USA. Show all posts
Showing posts with label USA. Show all posts

Jian Zhang, a member of the US Department of Defense medical project review committee since 2004, is the CCP's Candidate of "National Hundred Thousand Talents Project" and Special Expert of the State Council

 Zhang Jian

professor
National-level candidate for the Hundred Thousand Talents Project
0755-88018036
zhangjian@sustech.edu.cn




Introduction to main academic achievements

Zhang Jian, Professor of School of Medicine, Southern University of Science and Technology, Doctoral Supervisor, Dean of Zhicheng Academy, National Candidate of "Hundreds of Thousands of Talents Project", Special Expert of the State Council, National Leading Talents introduced by Shenzhen, Cancer Metastasis of China Anti-Cancer Association Member of the Standing Committee of the Professional Committee and Chairman of the Youth Committee, Vice Chairman of the Translational Medicine Branch of the Chinese Society of Medicine and Biotechnology, Member of the Standing Committee of the Medical Cell Biology Branch of the Chinese Society of Cell Biology, Vice President of Shenzhen Biomedical Promotion Association, Shenzhen Alliance of China Anti-Cancer Alliance Vice-Chairman, who founded the "Longevity and Aging-related Diseases" Key Laboratory of the Ministry of Education and served as the first director, currently serves as a member of the Academic Committee of the Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research and the Academic Committee of the Shenzhen Key Laboratory of Cell Microenvironment. From 2015 to 2017, he served as the associate editor of "Medical Oncology". SCI has published more than 100 articles in total. He graduated from the University of Michigan School of Medicine with a Ph.D., and has been a member of the US Department of Defense medical project review committee since 2004. Since 2009, he has been a Changjiang Scholar of the Ministry of Education and a final review expert of the Natural Science Foundation of my country. In 2012, he was selected as "National Outstanding Scientific and Technological Worker", and in 2013, he was selected as "National Hundred Thousand Talents Project" and "National Young and Middle-aged Experts with Outstanding Contributions". In 2016, it was approved as "Shenzhen Introduces National Outstanding Talents". Main research directions: aging basis and intervention; tumor microenvironment and metastasis.

 

Research areas

Oncology Translational Medicine Research

Tumor drug resistance, recurrence and metastasis

Aging and Cancer

 

educational experience

1981-1986: Bachelor, Department of Clinical Medicine, Tianjin Medical University

1997-1998: M.S., Immunology, Old Dominion University & East Virginia Medical School

1998-2001: Ph.D., Pathology, University of Michigan

 

main working experience

1986.8-1995.1 Tianjin Third Hospital/Tianjin Institute of Geriatrics, Internal Medicine Resident, Attending Physician

1995.1-1996.8 Visiting Scholar, World Health Organization Fellowship, Institute of Geriatrics, University of Wisconsin-Madison, USA

1996.8-1998.8 Visiting Research Scientist, Eastern Virginia Medical College Geriatrics Research Center

1998.8-2004.6 Ph.D. student/researcher, University of Michigan School of Medicine

2004.7-2010.12 Assistant Professor at University of Pittsburgh and University of Michigan School of Medicine (Tenure track)

2011.1-2016.7 Ministry of Education Key Laboratory of Longevity and Age-related Diseases/Director/Professor of Guangxi Medical University Translational Medical College

2016.3- Adjunct Professor, University of Pittsburgh School of Medicine

2016.7- Professor, School of Medicine, Southern University of Science and Technology

 

honor

2019-Vice President of Shenzhen Biomedical Promotion Association

2018- Vice Chairman of Shenzhen Alliance of China Cancer Prevention and Control Alliance

2014- Obtained the Special Government Allowance Expert of the State Council

2013-Selected as a national candidate for the National Hundred Thousand Talents Project and won the honorary title of "Young and Middle-aged Experts with Outstanding Contributions"

2013-International lecturer certificate issued by American Society for Basic Urological Research (SBUR)

2012-National Outstanding Scientific and Technological Workers

2011-Bagui Scholar of Guangxi Autonomous Region, Counselor of Guangxi Autonomous Region Government

2007-Mentoring Dr. Yi Lu, Young Investigator Travel Award, ASBMR

2005-Mentoring Dr. Yi Lu, Scholar-in-Training Award, AACR

2003-Scholar-in-Training Award, AACR

2003- Plenary Poster Award of 25th Annual Meeting of American Society for Bone and Mineral Research

2002-Alice L. Jee Memorial Young Investigator Award

2000-Plenary Poster Award of 22 nd Annual Meeting of American Society for Bone and Mineral Research

1994- Fellowship Award, World Health Organization (WHO)

 

representative works

  1. Zhang J , Dai J, Qi Y, Lin D, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest. 107:1235-1244, 2001.
  2. Zhang J , Johnston G, Stebler B, Keller ET. Oxidative stress-mediated activation of NFkB and the interleukin-6 promoter requires NFkB-inducing kinase activity. Antioxidant & Redox Signaling . 3:493-504, 2001.
  3. Zhang J , Dai J, Lin D, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET. Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. J Bone Miner Res 17:1256- 1263, 2002.
  4. Zhang J , J Dai, Yao Z, Lu Y, Dougall W, Keller ET. Soluble RANK-Fc diminishes prostate tumor progression in bone. Cancer Res. 63:7883-90, 2003
  5. Zhang J , Lu Y, Kitazawa R, Kitazawa S, Dai J, Qi W, Zhao X, Yao Z, Hall D, Keller ET. Bioluminescence imaging of RANK ligand transcriptional regulation in vivo. Prostate. 59:360-9, 2004
  6. Zhang J , Dai J, Lu Y, Yao Z, O'Brein C, Qi W, Hall D, Ershler WB, Keller ET. In vivo visualization of aging-associated gene transcription: evidence for free radical theory of aging. Experimental Gerontology. 39:239-247, 2004
  7. Lu Y, Cai Z, Galson DL, Xiao G, Liu YL, George D, Melhem MF, Yao Z and Zhang J*. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate. 66:1311-8, 2006
  8. Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD, Zhang J*. Monocyte chemotactic protein-1 (MCP-1) mediates prostate cancer-induced bone resorption. Cancer Res, 67:3646- 53, 2007
  9. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, and Zhang J*.    CCR2 expression correlates with prostate cancer progression. J Cell Biochem. 101:676-685, 2007
  10. Lu Y, Yao Z, and Zhang J*. Prostate cancer bone metastasis: interaction between tumor cells and bone microenvironment. Chin J of Biochem and Molecul Biol , 23(3):167-171, 2007
  11. Lu Y, Xiao G, Galson DL, Nishio Y, Mizokami A, Yao Z, and Zhang J*. PTHrP-induced MCP-1 production by human bone marrow endothelial cells promotes osteosteoclastast differentiation and prostate cancer cell proliferation and invasion in vitro.   Int J of Cancer. 121:724-733, 2007
  12. Lu Y, Nie DB, Witt WT, Chen Q, Shen M, Xie H, Lai L, Dai Y, Zhang J*. Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3β phosphorylation . Mol Cancer Therapeutics, 7(10):3203-11, 2008
  13. Lu Y, Wang J, Xu Y, Koch AE., Cai Z, Chen X, Galson DL, Taichman RS, and Zhang J*. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol Cancer Res, 6( 4): 546-54, 2008
  14. Lu Y, Chen QY, Corey E, Xie W, Fan J, Dai J, Mizokami A, and Zhang J*. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis, 26(2): 161-9, 2009
  15. Cai Z, Chen QY, Chen J, Lu Y, Xiao GZ, and Zhang J*. MCP-1 promotes lung cancer-induced bone resorptive lesions in vivo. Neoplasia , 11(3):228-236, 2009
  16. Zhang J, Patel L, and Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 21(1):41-8, 2010
  17. Zhang J, Lu Y, and Pienta KJ. Multiple roles of CC chemokine ligand 2 (CCL2) in promoting prostate cancer growth. J Natl Cancer Inst. 102(8):522-8, 2010
  18. Zhang J*, Sud S, Mizutani K, Gyetko MR, and Pienta KJ. Activation of urokinase plasminogen activator (uPA) and its receptor (uPAR) axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia 2011
  19. Zhang J, Patel L, Pienta KJ. Targeting Chemokine (CC motif) Ligand 2 (CCL2) as an Example of Translation of Cancer Molecular Biology to the Clinic. Progress in Molecular Biolology: Translational Sciences. 2010;95:31-53.
  20. Guo H, Yun C, Hou G, Du J, Huang X, Lu Y, Keller ET, Zhang J*, Deng J*, Mangiferin attenuates Th1/Th2 cytokine imbalance in an ovalbumin-induced asthmatic mouse model. Plos One . 9( 6):e100394, 2014
  21. Guo H, Lu Y, Wang J, Liu X, Keller ET, Liu Q, Zhou Q, Zhang J *. Targeting Notch Signaling Pathway in Cancer Therapeutics. Thoracic Cancer , 2014, 5; 473-86
  22. Hongwei Guo, Xiaolin Zhou, Yi Lu, Liye Xie, Qian Chen, Evan T. Keller, Qian Liu, Qinghua Zhou* , and Zhang J* . Translational progress on tumor biomarkers. Thoracic Cancer. 27 JUL 2015, DOI: 10.1111/1759 -7714.12294
  23. Yu Zhu, Chunlin Zou, Zhe Zhang, Chaonan Qian, Xin Yang, Junlin Shi, Yudui Xia,   Zhang J* , Yi Lu*. MEK inhibitor diminishes nasopharyngeal carcinoma (NPC) cell growth and NPC-induced osteoclastogenesis via modulating CCL2 and CXCL16 expression . Tumor Biology , 2015, 36(11):8811-8.
  24. Sha He, Yi Lu, Xia Liu, Xin Huang, Evan Keller, Chao-Nan Qian * ,   Zhang J * ; Wnt3a: function and implication in cancer. Chinese Journal of Cancer , 2015, 34(3):50.
  25. Lihui Wang, Yanli He, Weijun Liu, Shengbin Bai, Lei Xiao, Jie Zhang, Saravana M. Dhanasekaran, Zhuwen Wang, Shanker Kalyana-Sundaram, O. Alejandro Balbin, Sudhanshu Shukla, Yi Lu, Jules Lin, Rishindra M. Reddy, Philip W. Carrott, Jr., William R. Lynch, Andrew C. Chang, Arul M. Chinnaiyan, David G. Beer*, Zhang J *, Guoan Chen*. Non-coding RNA LINC00535 promotes lung adenocarcinoma progression via the Akt pathway . Oncotarget, 7(10):11487-99, 2016.
  26. Jing Li, Xin Yang, Hao Guan, Atsushi Mizokami, Evan T. Keller, Xiaozhen Xu, Xia Liu, Jiyong Tan, Longyuan Hu, Yi Lu*, Zhang J* . Exosome-derived microRNAs contribute to prostate cancer chemoresistance. International Journal of Oncology , 2016, 49:838-846.
  27. Yeguo Yang, Yi Lu, Lihui Wang, Atsushi Mizokami, Evan T. Keller, Zhang J* , Jiejun Fu*. Skp2 inhibition attenuates the resistance of prostate cancer cells to paclitaxel by up-regulation of p27. Oncology Reports , 2016, 36: 559-566.
  28. Yang Liu, Yi Chai, Zhang J * , and Junwei Tang * . A function variant at miR-501 alters susceptibility the patocellular carcinoma in a Chinese han population. Cell Physiol Biochem, 38(6):2500-8, 2016.
  29. Qiuyan Chen, Siyuan Qin, Yang Liu, Minghuang Hong, Chao-Nan Qian, Evan T Keller, Zhang J , Lu Y*. IGFBP-6 is a novel nasopharyngeal carcinoma prognostic biomarker. Oncotarget , 2016, Oct 18;7(42) :68140-68150.
  30. Yong Lei, Yanhua Yi, Yang Liu, Xia Liu, Evan T. Keller, Chao-Nan Qian, Jian Zhang* and Lu Y*. Metformin targets multiple signaling pathways in cancer. Chinese Journal of Cancer , 2017; 36(1): 17.
  31. Guo H, Luo H, Yuan H, Xia Y, Shu P, Huang X, Lu Y, Liu X, Keller ET, Sun D*, Deng J*, and Zhang J* . Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3β signaling. Sci Rep . 2017; 7: 41656.
  32. Wenchu ​​Wang, Lihui Wang, Atsushi Mizokami, Junlin Shi, Chunlin Zou, Jinlu Dai, Evan T. Keller, Yi Lu* and Jian Zhang* . Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Chinese Journal of Cancer , 2017; 36:35
  33. Yutao Gao, Xia Liu, Ting Li, Luwei Wei, Antai Yang, Yi Lu, Jian Zhang, Li Li, Sumei Wang and Fuqiang Yin. Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer. Oncology Reports. 2017
  34. Jinlu Dai, Yi Lu, Hernan Roca, Jill M. Keller, Jian Zhang , Laurie K. McCauley and Evan T. Keller. Immune mediators in the tumor microenvironment of prostate cancer. Chinese Journal of Cancer , 2017; 36:29

Links to orginal content: 
1. https://www.sustech.edu.cn/zh/faculties/zhangjian.html
2. https://med.sustech.edu.cn/faculty/detail/id/187.html?lang=zh-cn

Guoqiang Chen,Chief Scientist of the National Key Basic Research (973) Program, and National Candidate for the "Hundreds and Thousands of Talents Project",1999-2001, engaged in cooperative research at the Mount-Saint Medical School of USA

 Chen Guoqiang, male, born in 1963, from Youxian County, Hunan Province, Ph.D., is currently the Vice Dean of Shanghai Jiaotong University School of Medicine, Dean of the Academy of Medical Sciences and Dean of the Graduate School, Director of the Key Laboratory of Cell Differentiation and Apoptosis of the Ministry of Education, Director of the Department of Pathophysiology, Executive Director of the Chinese Society of Pathophysiology, Vice Chairman of the Shanghai Society of Biochemistry and Molecular Biology, Vice Chairman of the Shanghai Physiological Society, Deputy Editor-in-Chief of Acta Physiologica Sinica, Cancer, and International Journal of Pathology and Clinical Sciences , "OpenHematologyJ", "ActaPharmacologySina", "Chinese Medical Journal", "Science Bulletin", "China Science-Life Science Series", "Chinese Journal of Cancer Biotherapy", "Chinese Journal of Cancer Prevention and Treatment" and other editorial board members. Winner of the National Science Fund for Distinguished Young Scholars, Chief Scientist of the National Key Basic Research (973) Program, and National Candidate for the "Hundreds and Thousands of Talents Project". In July 1996, he obtained a doctorate in medicine from Shanghai Second Medical University (now Shanghai Jiaotong University School of Medicine), and in 1997 and 1999-2001, he engaged in cooperative research at the Saint-Louis Hospital in Paris, France, and the Mount-Saint Medical School in the United States. 

  For many years, he has been devoted to the molecular mechanism and basic therapeutic research of leukemia cell differentiation and apoptosis. His basic and clinical research work on the treatment of acute promyelocytic leukemia with arsenic trioxide has attracted great attention from international counterparts. After returning to China in May 2002 and serving as the director of the pathophysiology teaching and research section of Shanghai Jiaotong University School of Medicine, a teaching and research section with only ten employees, less than 10,000 yuan of scientific research assets, and no scientific research projects has achieved leap-forward development. In the past few years, on the basis of his discovery of hypoxia-induced leukemia cell differentiation, he proposed a signaling mechanism for leukemia cell differentiation based on "hypoxia-hypoxia-inducible factor (HIF-1a)-C/EBPa"; reported that phospholipid crawling enzyme-mediated It can induce leukemia differentiation and make new discoveries on its expression regulation mechanism; it is found that a new type of camptothecin derivative NSC606985 can induce leukemia cell apoptosis at low concentrations, and its mechanism of inducing apoptosis has been studied, showing good results. Prospects for drug development. In addition, important progress has also been made in the use of proteomic techniques to study the functions of leukemia-related proteins.

  So far, he has published more than 60 papers in important international academic journals such as JNCI, BLOOD, JBC, ONCOGENE, LEUKEMIA, CANCERRES, etc. Since 1997, it has always been in the top eight in the national ranking of single paper citations, with a total of more than 2,700 times. He has also successively won the second prize of the National Natural Science Award, the first prize of the Shanghai Science and Technology Progress Award, the DuPont Science and Technology Innovation Award, the China Youth Science and Technology Award, the first prize of the Shanghai Medical Science and Technology Award, the China Medical Science and Technology Award and other academic awards and national and Shanghai model workers. , the first batch of candidates for the National Hundred Thousand Talents Project in the New Century, Shanghai Science and Technology Talents, Shanghai Outstanding Discipline Leader, Shanghai Natural Science Peony Award and other honorary titles.


 

medical school

  Academician of the Chinese Academy of Sciences

  Chief Scientist of "973"

  National Science Fund for Distinguished Young Scholars

  famous alumni

  Thousands of talents

 

Wednesday, January 19, 2022Today is:President's speech


Alumni Association President to 2011...

  Tian Xingjian, unremitting self-improvement, Longteng medicine has a broad road; terrain is Kun, great virtue carries things, Lin Tuyushu is a new beginning. May the teachings of Boji Hospital, diligent and tireless continue to guide you, not to admire the impetuous publicity, but to be willing to serve in loneliness.

More..

 


Shanghai ICP No. 05052044 Copyright ? 2009 Shanghai Jiaotong University Hospital No. 227 Chongqing Road, Shanghai, China Postcode: 200025 Tel: 021-63846590


---Links---

 


Chen Guoqiang, born in November 1963, is a professor of medical pathophysiology and an academician of the Chinese Academy of Sciences. He is currently the dean of Shanghai Jiaotong University School of Medicine, deputy secretary of the party committee, vice president of Shanghai Jiaotong University, and representative of the 15th Shanghai Municipal People's Congress.                              

     

Professor Chen Guoqiang graduated from the former Shanghai Second Medical University in 1988 and 1996 with a master's degree in medicine and a doctorate in medicine, respectively. On July 1, 1997, he joined the Communist Party of China. In 1997 and 1999-2001, he was a visiting scholar in Paris, France and New York, USA respectively.                              

     

Since he was awarded the National Science Fund for Distinguished Young Scholars in 1997, especially since he served as the director of the Pathophysiology Teaching and Research Section of Shanghai Second Medical University in 2002, he has taken the lead and worked hard, successively as the chief scientist to undertake the National Key Basic Research (973) Project and the National Major Scientific Research Planning projects, and as the leader of a number of key projects of the National Natural Science Foundation of China, major projects and leaders of innovation groups, leading research teams, dedicated to tumor, especially acute myeloid leukemia (AML) cell fate determination and tumor microenvironment regulation mechanism Research. In terms of hypoxic microenvironment, it was found that hypoxia induces AML cell differentiation through the non-transcriptional function of hypoxia-inducible factor-1 (HIF-1), and revealed that Cbx4 modifies HIF-1α through ubiquitination to control hepatocellular carcinoma angiogenesis In the aspect of stress microenvironment, the mechanism of leukemia stem/progenitor cells to induce differentiation of bone marrow mesenchymal cells to form a new bone marrow microenvironment and the mechanism of environmental protection of leukemia cells in this microenvironment were discovered; in the aspect of chemical biology, it was found that Several antitumor natural compounds, especially adenine, were found to induce AML cell differentiation by targeting members of the peroxidoreductase family. Relevant research results have published more than 160 SCI papers in important international academic journals such as Cancer Cell, Nat Chem Biol, J Clin Invest, Nat Cell Biol, Blood, Leukemia, EMBO Report, Oncogene and other journals, and have been cited more than 7,000 times by him. He has successively won the second prize of the National Natural Science Award, the first prize of the Chinese Medical Science and Technology Award, the first prize of the Shanghai Natural Science Award, and the first prize of the Shanghai Science and Technology Progress Award. Young Expert, National Excellent Doctoral Dissertation Instructor, National Advanced Worker, Changjiang Distinguished Professor of the Ministry of Education, the first batch of national candidates for the New Century Hundred Thousand Talents Project, China Youth Science and Technology Award, Shanghai Model Worker, Shanghai Top Ten Outstanding Young People , Shanghai Science and Technology Talents, Shanghai Excellent Returnees from Overseas Study, Shanghai Medical Leading Talents, Shanghai Natural Science Peony Award and other honorary titles. He has also been invited to serve as the editorial board of many academic journals at home and abroad and honorary professors such as the University of Sydney and the University of Ottawa. Association Member of the Steering Committee of Academic Health Centers International.                              

     

In 2006 and 2010, Professor Chen Guoqiang served as the vice dean of the medical school in charge of scientific research and graduate students and the dean of the medical school in charge of administrative work respectively. He has always followed the development law of comprehensive universities, followed the special laws of medical disciplines, and set an example. , with the passion and perseverance of "success does not have to be mine, and skill must not be donated", determined to reform, committed to the discipline construction of "world-class, Chinese characteristics, Shanghai style and medical characteristics" and outstanding medical innovation talents with soul Cultivation work. He has always emphasized that through both introduction and education, talents are selected and used well, and the vitality of talents is activated. Motivating each other and transcending together, making students more excellent, making teachers more outstanding, and producing innovative ability and wisdom that will benefit both teachers and students for life." The innovative culture of passion, dreams and determination builds a synergistic and inclusive development system of teaching, scientific research, medical treatment and management, and realizes the rapid development of the medical school.                              

     

Dean Chen Guoqiang was an associate researcher, researcher (1997-2002) and deputy director (2001-2002) of Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Second Medical University, Basic Medicine of Shanghai Second Medical University/Shanghai Jiaotong University Director of the Department of Pathophysiology (2002-2009), Deputy Dean of Shanghai Jiaotong University School of Medicine (2006-2010), Dean of the Graduate School (2006-2009), and concurrently dean of the School of Basic Medicine and the Academy of Medical Sciences (2007-2010).



Sheng Jiang, NCI/NIH researcher,returned to China at the end of 2007 and is now a researcher and doctoral supervisor of theCAS "Hundred Talents Program"

 Academic Report of Researcher Jiang Sheng, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences

author:     Source: China Pharmaceutical University     Hits: 1563     Update Time: 2015-07-07

Report title : Discovery of Novel Class I Histone Deacetylase

Inhibitors through Total Synthesis of Natural Products

Report time : July 10 , 2015 (Friday) 9 :30-11:00

Location of the report: Lecture Hall 307 , Academic Exchange Center, Xuanwumen Campus

Speaker : Jiang Sheng, researcher, Chinese Academy of Sciences "Hundred Talents Program" researcher

Brief introduction : Jiang Sheng, Ph.D., researcher, graduated from China Pharmaceutical University in 1997 and 2000 with a bachelor's degree and a master's degree, respectively, and graduated from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences with a doctorate in 2003 . From 2003 to 2007 , he was engaged in postdoctoral research at the National Cancer Institute of the US Department of Health ( NCI/NIH ) and won the " NIH Fellows Award for Research Excellence ". He returned to China at the end of 2007 and is now a researcher and doctoral supervisor of the "Hundred Talents Program" of the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences . He is also a member of the American Chemical Society, a member of the American Peptide Society, a member of the Chinese Chemical Society, and a senior member of the Chinese Pharmaceutical Association. The research group is mainly engaged in the research of total synthesis of natural products and medicinal chemistry. He has won the 973 project, the major project of "Major New Drug Creation Technology", and the National Natural Science Foundation of China.More than 10 scientific research projects . So far, more than 60 SCI papers have been published in internationally renowned journals such as Angew. Chem. Int. Ed. , J. Med. Chem. , J. Am. Chem.Soc , Org.Lett .

    All teachers and students are welcome to come!

                                       School of Pharmacy, Science and Technology Office

                                            July 7 , 2015 _ _

Jiang Sheng

Personal profiles:

Name :Jiang Sheng Gender :                  male      

Date of Birth :June 14 1976 _      Specialties : Medicinal Chemistry        

Education : Doctor of Science Professional Technical Position : Professor, Doctoral Supervisor           

E-mail jiang_shengg 126.com    Telephone  (Tel.) 18688888237

 

learning experience

1993 9-1997 : China Pharmaceutical University, Medicinal Chemistry, Bachelor 

1997 9-2000 : China Pharmaceutical University, Medicinal Chemistry, Master

2000 9-2003 : Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Organic Chemistry, Ph.D.

 

work experience

2003 11-2007 11 : National Institutes of Health ( NIH ) Cancer Institute ( NCI ); Medicinal Chemistry, Postdoc

2007 12-2016 , 12 : Guangzhou Institute of Biology and Health, Chinese Academy of Sciences, medicinal chemistry, doctoral supervisor ,Research group leader.

2017,1 PRESENT : China Pharmaceutical University, medicinal chemistry, doctoral supervisor ,Research group leader.

 

Main academic achievements, scientific and technological achievements and innovations

 Dr. Jiang Sheng graduated from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences in 2003 with a Ph.D. in organic chemistry. From 2003 to 2007 , he worked as a postdoctoral researcher at the National Cancer Institute ( NCI/NIH ) of the U.S. Department of Health. After returning to China in 2008 he served as a researcher and doctoral tutor of the "Hundred Talents Program" of Guangzhou Institute of Biomedicine and Health , Chinese Academy of Sciences .Research group leader Now he is a doctoral supervisor of the Department of Medicinal Chemistry, China Pharmaceutical University .Research group leader. He is also a member of the American Chemical Society, a member of the American Peptide Society, a member of the Chinese Chemical Society, and a senior member of the Chinese Pharmaceutical Association. Employed for several international journals such as J. Med Chem. Bioorg. Med. Chem. Lett. , Bioorg. Med. Chem. Eur. J. Med Chem.  J. Org. Chem , Organic LettersSpecial reviewer for other journals, and review expert for projects such as the National Natural Science Foundation of China. In recent years, a total of 68 SCI papers have been published, including a series of innovative articles published in the international core journals Angew. Chem. Int. Ed., Organic Letters, Journal of Medicinal Chemistry and Journal of The American Chemical Society . Among them, " Rationally Designed Inhibitors Identify STAT3 N-Domain as a Promising Anticancer Drug Target " was published in the international publication ACS Chemical BiologyAfter it was published, it aroused strong interest from international peers and was selected as one of the most-accessed articles of the 1st quarter of 2008 .

  At the same time, research on the following projects was completed:

1.   Completed the design and synthesis of the anti-tumor natural product Annonaceous Acetogenins analogs. We used the natural annua lactone- Bullatacin as a template, simplified the double tetrahydrofuran ring into a ethylene glycol diether structure retained its basic skeleton, and used the concepts of rational drug design, parallel synthesis, fragment assembly, etc. to effectively establish annua lactone. A library of analog molecules with completely new chemical structures. Among them, the activity of compound AA019 on HT-29 tumor cells was 15 times that of doxorubicin , and it was not toxic to normal cells. In the in vitro test, the compound AA019 can effectively inhibit the growth of  lewis lung cancer in nude mice at an oral dose of 10 mg/kg (compared with the control group, the inhibition rate is more than 60% ). Currently, the compound is in preclinical studies. 

2.    Completed the design and synthesis of natural cyclic peptide ( SFTI-1 ) analogs. Using the binding model of SFTI-1 and protease, a series of novel cyclic peptides were successfully designed and synthesized by computer-aided drug design method. Among them, SFTI-15 had better proteolytic activity ( Ki = 10 nM ) and It has good selectivity and stability. Moreover, further in vivo and in vitro experiments showed that it can effectively inhibit tumor growth.

3.    Completed the design and synthesis of Grb2-SH2 polypeptide inhibitors. Taking G1TE as the lead, the design, synthesis and structure-activity relationship of G1TE analogs were systematically carried out . Among them , the activity of G177 on Grb2-SH2 is more than 1000 times that of G1TE A batch of Grb2-SH2 antagonists with cell-level tumor growth inhibitory activity were also discovered during development, providing promising pharmacophore patterns and lead compounds for anti-tumor drug candidates.

4.   Completed the design and synthesis of cyclic peptide inhibitors of STAT-3 . This work was published in "ACS Chemical Biology" titled "Rationally Designed Inhibitors Identify STAT3 N-Domain as a Promising Anticancer Drug Target" and was named the most-accessed article of the first quarter of 2008 by ACS . 1st quarter of 2008 ).

5.   Participated in the University of Michigan as one of the main collaboratorsWang ShaomengProfessor presided over the new anti-tumor drug AT-101 , a broad-spectrum inhibitor of Bcl-2 family proteins, a Spirooxindole class of p53-MDM2 interaction blockers, isoflavone class Bcl-2 family protein inhibitors and protein IAP small molecule inhibitors, etc. Development of antineoplastic drugs.

6.   Completed the design and synthesis of selective inhibitors of histone deacetylation type I enzymes. Among them, the median inhibitory concentration ( IC50 ) of compound Lar-7 on tumor cell lines can reach as low as 1.0 nM 26 cell line experiments in vitro showed that the IC50 for multiple series of tumor cells was between 1-40 nM ), and the anti-tumor activity was A similar drug vorinostat ( SAHA ) has been listed abroad 10-100 times; and it is non-toxic to normal cells. The preliminary in vivo pharmacodynamic evaluation and acute toxicity evaluation of Lar-7 also reflect its low toxicity and high efficiency: it is resistant to human prostate cancer Du-145 , human breast cancer MDA-MB-231 and human leukemia imatinib Cells ( T315I ) subcutaneously transplanted tumor in nude mice had obvious inhibitory effect, and the relative tumor proliferation rates ( T/c% Day-21 ) were 29.64%  20% and 37% , respectively Preliminary acute toxicity test showed that the LD50 of Lar-7 in Kunming mice256.2 mg/kg ) is far greater than that of the similar drug Romidepsin 3.6 mg/kg ) that has been marketed abroad, showing extremely low toxicity. Currently, the compound is in preclinical studies.

7.   Design and synthesize a new biotin-labeled cyclic peptide compound , and successfully  " catch a new protein  "r-catenin" with the labeled compound We verified and found that this protein is a key protein in the self-renewal of leukemia cancer stem cells and the compounds we designed can effectively overcome the problem of imatinib resistance by inhibiting this protein.

8.   Completed the design and synthesis of multiple inhibitors of EGFR, Her-2 and HDC . Among them, the median inhibitory concentration ( IC50 ) of compound JSNMPT-17 on multiple series of tumor cells is between 1-10 nM , and its anti-tumor activity is about 50 times that of a foreign phase II clinical drug ( CUC-101 ) . Currently , the in vivo pharmacodynamic evaluation of JSNMPT-17 is in progress.

9.   Completed the total synthesis of 7 natural products they are Largazole, FK-228, Argyrins A and E, (-)-Norsecurinine, (+)-Niruroidine and Flueggine A.

10.  Completed the design and synthesis of IDO inhibitors. Among them, the antitumor activity of the compound JQIDO-003 is comparable to that of foreign phase II clinical drugs. Currently , the in vivo pharmacodynamic evaluation of  JQIDO-003 is ongoing.

 

Major scientific research projects hosted in the past five years

 


serial number

Subject name

Numbering

host or participate

Start and end time

expenses

10,000 yuan )

category

1

Synthesis of Compounds and Derivatives with Stem Cell Regulation Activity

2009CB940904

host

2009.1-

2013.12

6.9 million

973 project sub-topics

2

Study on the simplified analog AA-005 of annua lactone as an anticancer drug

2009ZX09103-101

host

2009.1-

2010 12

1.26 million

National New Drug Innovation Major Project

3

Structure-activity relationship and antitumor activity of histone deacetylase inhibitor Lar-7

21172220 

 

host

2012.1-

2015.12

600,000 _

National Natural Science Foundation of China

surface item

4

Total Synthesis of Argyrin A

20972160

host

2010.1-

2012.12

350,000 _

National Natural Science Foundation of China

surface item

5

Proteolytic enzyme cyclic peptide inhibitor and its antitumor activity

20802078

host

2009.1-

2011.12

180,000 _

National Natural Science Foundation of China

Youth Fund

6

Design and Synthesis of Cyclic Peptide Inhibitors of Proteolytic Enzymes

NNCAS-2008-8

host

2009.1-

2010 12

500,000 _

Novartis Nordisk Chinese Academy of Sciences Joint Fund

7

Proteolytic enzyme inhibitors and their antitumor activity

KSCX2-YW-R-215

host

2010.1-

2010.12

200,000 _

Important direction project of knowledge innovation project of Chinese Academy of Sciences

8

Design and synthesis of small molecule inhibitors of proteolytic enzymes

 

8151066302000008

host

2009.1-

2011.12

 

50,000 _

 

Natural Science Foundation of Guangdong Province

 

9

Total Synthesis of Flueggines A and B

21472191

host

2015.1-

2018.12

900,000 _

National Natural Science Foundation of China

surface item

10

Study on AA-005 as Anticancer Drug

2013A022100019

participate

2015.1-

2017.12

1.5 million

Guangdong Province New Drug Creation Project

11

Construction of Molecular Probes for Histone Deacetylation Type Enzymes and Research on Early Diagnosis and Treatment

2016A050502036

host

2016.1-

2018.12

500,000 _

Guangdong Province International Cooperation Project

12

Molecular probes of histone deacetylation type enzymes as early diagnosis and treatment of tumors

 

host

2017.5-

2020.4

million

Guangzhou Industry-University-Research Collaborative Innovation Major Project


 

Invited report

 

1. Sheng Jiang  (invited speaker), “Discovery of Novel Class I Histone Deacetylase Inhibitors through Total Synthesis of Natural Products”, National Cancer Institute 2015 (2015,10,20FredercikUS).

2. Sheng Jiang  (invited speaker), “Discovery of Novel Class I Histone Deacetylase Inhibitors through Total Synthesis of Natural Products”, Chinese Pharmaceutical University 2015 (2015,7,10NanjingChina).

2. Sheng Jiang  (invited speaker), "Discovery of Novel Class I Histone Deacetylase Inhibitors through Total Synthesis of Natural Products", The 4th Natural Product Total Synthesis - Youth Symposium (2015,7, Chengdu , China).

3.  Sheng Jiang  (invited speaker), "Discovery of Novel Class I Histone Deacetylase Inhibitors", 10th National Natural Organic Chemistry Conference of Chinese Chemical Society  (2014,11 Guangzhou, China).

4.  Sheng Jiang  (invited speaker), “Design, Synthesis and Biological Evaluation of Novel Class I Histone Deacetylase Inhibitors through Total Synthesis of Natural Products”, 2012 ( Shanghai , China).

5. Sheng Jiang  (invited speaker), “From Total Synthesis of Natural Products to Discovery of New Histone Deacetylase Inhibitors”, The 4th China-Thailand Workshop on Natural Products and Drug Discovery, Trang Province, Thailand, November 26-30, 2012

6. Sheng Jiang  (invited speaker), “Discovery of New Histone Deacetylase Inhibitors”, The 28th CCS National Congress (2012,ChenduChina)

7. Sheng Jiang  (invited speaker), “Design and synthesis New Histone Deacetylase 1 (HDAC1) inhibitors as potential anticancer drugs”, National Cancer Institute, Frederick, MD, 2010

8. Sheng Jiang  (invited speaker), “Total Synthesis of Largazole and its analogues potential anticaner drugs”, The 5 th  CCS National Congress on organic chemistry (2009, Xian,China).

9. Sheng Jiang  (invited speaker), “Potent antagonists of the Grb2-SH2 domain: Not relying on phosphotyrosine mimics”, Chinese Pharmaceutical University 2006 (2006,NanjingChina).

 

10. Sheng Jiang ,  et al. “Potent antagonists of the Grb2-SH2 domain: Not relying on phosphotyrosine mimics”, 232 th  American Chemical Society Meeting (9/10-9/14, 2006).

11. Sheng Jiang ,  et al. “Synthesis and Evaluation of Analogs of SFTI-1, Potent Inhibitors of the Type II Transmembrane serine protease, Matriptase”, 230th American  Chemical Society Meeting (8/28-9/1, 2005).

12. Sheng Jiang ,  et al. “Synthesis of Symmetrical Dimeric Dicarboxylic Acid Linked Peptides on Solid support”, 19th American  Peptide Symposium (6/18-23, 2005).

13. Sheng Jiang , et al. “First Chemical Synthesis of Butenolide2", The 2 nd  CCS National Congress on organic chemistry and the 1 st  CCS National Congress on Chemical Biology (2002, China).

 

Awards and Honors:

2011  The 14th Chinese Pharmaceutical Association - Servier Youth Medicinal Chemistry Award

20 10     Hundred Talent Award

20 07 NIH Fellows award for the Research Excellence            

1996      Excellent Student  Scholarship

 

Patent

 

1.   “Synthesis and application of ether bond modified chiral annonaceous acetogenins compound”

Licensed to Shanghai Institute of Organic Chemistry

Inventors: ZJ Yao, YL Wu and S. Jiang.

Patent No. CN1477103

2.   “Method for synthesis of largazole and its analogs as antitumor agents.”

Inventors: S. Jiang, G. Zhou, B. Yin, X. Zeng, and Z. Hu.

Patent No. CN 101781321

3.  “Annonaceous acetogenins analogs as antitumor agents and their preparation, pharmaceutical compositions and use in the treatment of cancer”

Inventors:  S. Jiang,  ZJ Yao, G. Zhou, Q. Xiao, Y. Liu

Patent No. CN 101982464

4.   “Preparation of cyclopeptides as histone deacetylase inhibitors”

Inventors: S. Jiang,  S. Li, Y. Yao, F. Zhang, Y. Chao, H. Ye, M. Chen 

CN Patent Serial No. CN102391359

5.   “Preparation of triazole compounds as histone deacetylase inhibitors.”

Inventors: S. Jiang, Z.Tu, Y. Yao, C. Liu, H. Yao, X. Xue,

Patent No. CN 102311398

6.  “Process for preparation of FK228”

Inventors:  S. Jiang,  J. Xu, S. Li, H. Yao, X. Zeng,   Y. Yao,

Patent No. CN 102276689

7.        “Quinoxalinyl bis(N-oxide) derivatives and their application as ligands in Cu-catalyzed CO coupling reaction”

Inventors: Z. Yao,  S. Jiang, 

Patent No. CN 102060790

8.        “Quinoline derivative-N-oxide ligands, their preparation method and application in NC coupling”

Inventors:  Z. Yao,   S. Jiang, 

Patent No. CN 101899003

9.                  “Method for preparing epichlorohydrin tetramer and its reaction with   formaldehyde derivative”

      Inventors:  D. Zhang, J. Su, S. Jiang, 

Patent No. CN 103864727

10.    “Preparation of largazole analog compounds as antitumor agents”

      Inventors: S. Jiang,  Z. Tu, X. Li, Y. Yao, Y. Qiu

Patent No. CN 103601742

11.   “13-membered cyclic peptide as histone deacetylase inhibitor and its preparation”

    Inventors: H. Xiang, G. Wang, S. Jiang,  Z. Tu,

Patent No. CN 103232474

12.  "Preparation of N-containing heterocyclic derivatives as histone deacetylase I inhibitor"

Inventors: S. Jiang ,  Z. Tu, Q. Sun, C. Liu, Y. Yao, Y. Qiu,

Patent No. CN 103086971

13. “Preparation of 3-(pyridin-3-yl)acrylamide derivatives as nicotinamide phosphoribosyltransferase inhibitors useful for the treatment of cancer”

   Inventors: S. Jiang,  Z. Tu, D. Zheng, D. Qin, J. Bai, X. Qin, Y. Yao, Y. Liu, Y. Qiu, J. Chen

    Patent No. CN 104557863/PCT090572

 

  

 

Representative papers since engaging in scientific research

1.        J. Bai, , C. Liao, D. Qin, Y. Liu, X. Qing, J. Chen, Z. Li, Z. Tu, S. Jiang.* Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising In Vitro and in Vivo Antitumor Activities. J. Med. Chem . 2016 , 59 , 5766-5779.

2.       N. Ma, Y. Luo, Y. Wang, C. Liao, W.-C. Ye*, S. Jiang* .Selective histone deacetylase inhibitors with anticancer activity. Curr. Top. Med. Chem. 2016 , 16 , 415-426. 

3.       Y. Jin, Y. Yao, L. Chen, X. Zhu, B. Jin, Y. Shen, J. Li, X. Du, Y. Lu, S. Jiang* , J. Pan*.Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with imatinib.  Theranostics . 2016 , 6, 1947-1962.

4.       Y. Yao,Z. Tu,C. Liao, Z. Wang, S. Li, H. Yao, Z. Li, S. Jiang* .Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro Selectivity for Cancers Cells and in Vivo Antitumor Activities.  J. Med. Chem . 2015 , 58 , 7672-7680.

5.       Y. Yao,Z. Li, Y. Qiu, J. Su, S. Jiang* .Unprecedented reactions: from epichlorohydrin to epoxyglycidyl substituted divinyl ether and its conversion into epoxyglycidyl propargyl ether  Scientific Reports .  2015, 5 , srep14231.

6.       N. Ma, Y. Wang, B. Zhao, W.-C. Ye*, S. Jiang* .The application of click chemistry in the synthesis of agents with anticancer activity. Drug Design, Development and Therapy . 2015 , 50 , 1585-1599. 

7.        J. Zhang, H. Zhou, S. Jiang,  J. Jin, W. Li, W. Wang, S. Su. AA092, an annonaceous acetogenin mimetic, attenuates angiogenesis in a mouse model of inflammation-induced corneal neovascularization. International Immunopharmacology . 2015 , 28 , 997-1002.

8.       Y. Zhou, G. Hou, S. He, Z. Xiao, H. Xu, Y. Qiu,S. Jiang, H. Zheng, Z. Li. Psora-4, a Kv1.3 Blocker, Enhances Differentiation and Maturation in Neural Progenitor Cells. CNS Neuroscience & Therapeutics . 2015 , 21 , 558-567.

9.       N. Ma, Y. Yao, B.-X. Zhao, Y. Wang, W.-C. Ye*, S. Jiang* .Total synthesis of securinega alkaloids (-)-norsecurinine, (-)-niruroidine and (-)-flueggine A. Chem. Commun . 2014 , 50 , 9284-9287. 

10.    X. Zhu, L. Chen, S. Jiang , C. Chen, Y. Yao, D. Chen, H. Xue, J. Pan * .PQJS380: a novel lead compound to induce apoptosis in acute lymphoblastic leukemia cells. Cancer Biology & Therapy . 2014 , 15 , 119-127. 

11.    J. Su, Y. Qiu, S. Jiang*,  D. Zhang*.New Ligands for Copper-Catalyst C[n.63743]N Coupling Reactions at Gentle Temperature. Chinese Journal of Chemistry . 2014 , 32(8) , 685-688.

12.    J. Su, Y. Qiu, K. Ma, Y. Yao, Z. Wang, X. Li, D. Zhang, Z. Tu, S. Jiang* .Design, synthesis, and biological evaluation of larga zole derivatives: alteration of the zinc-binding domain. Tetrahedron. 2014 , 70 , 7763-7769.

13.     H. Zhou, S. Jiang,  J. Chen, X. Ren, J. Jin, SB Su*. Largazole, an inhibitor of class I histone deacetylases, attenuates inflammatory corneal neovascularization. European Journal of Pharmacology. 2014 , 740 , 619-626.

14.    H. Zhou,S. Jiang,  J. Chen, SB Su*. Suberoylanilide hydroxamic acid suppresses inflammation-induced neovascularization.Can. J. Physiol. Pharmacol. 2014 , 92 , 879-885.

15.    Y. Liu, Y. Liu, Z. Liu, G. Zhou, Z.-J.Yao* , S. Jiang* . Identification of novel bivalent mimetics of annonaceous acetogenins via a scaffold-hopping strategy.  Bioorg. Med. Chem. Lett. 2014 , 24 , 1650-1653.

16.    Y. Liu, Q. Xiao, Y. Liu, Z. Li, Y. Qiu, G.-B. Zhou, Z.-J.YaoS. Jiang* . Biological evaluation of new mimetics of annonaceous acetogenins: alteration of right scaffold by click linkage with aromatic functionalities. Eur. J. Med. Chem . 2014 , 78 , 248-258.

17.     Y. Yao, C. Liao, Z. Li, Z. Wang, Q. Sun, C. Liu, Z. Tu * , S. Jiang* . Design, Synthesis, and Biological Evaluation of 1, 3-Disubstituted- Pyrazole Derivatives as New Class I and IIb Histone Deacetylase Inhibitors.  Eur. J. Med. Chem . 2014 , 86 , 639-652. 

18.    Y. Zhao, X. Fang, Y. Wang, J. Zhang,  S. Jiang , Z. Liu, Z. Ma, L. Xu, E. Li, K. Zhang. Comprehensive Analysis for Histone Acetylation of Human Colon Cancer Cells Treated with a novel HDAC Inhibitor. Current Pharmaceutical Design . 2014 , 20 , 1866-1873.

19.     D. Zou, Y. Qiu, Z. Tu, C. Liao, J. Luo, Q. Meng, R. Yao, Z. Li, S. Jiang* .. Biological evaluation of 2-methylpyrimidine derivatives as active pan Bcr-Abl inhibitors. ScienceChina: Chemistry . 2014 , 57 , 823-832.

20.    Q. Meng, F. Li,S. Jiang, Z. Li*.Novel 64 Cu-labeled CUDC-101 for in vivo PET Imaging of histone deacetylases. ACS Medicinal Chemistry Letters . 2013 , 4, 858-862.

21.    L. Wu, Z. Wen, Y. Qiu, X. Chen, H. Chen, M. Wei, Z. Liu, S. Jiang*, G. Zhou*.Largazole arrests cell cycle at G1 phase and triggers proteasomal degradation of E2F1 in lung cancer cells; ACS Medicinal Chemistry Letters . 2013 , 4,  921-926.

22.    Y. Yao, H. Yao,S. Jiang*, X. Xue*.Progress in clinical study of histone deacetylase inhibitors as anticancer agents; Chinese J New Drugs . 2013 , 22  (3), 1-7.

23.    Q. Sun , Y. Yao,  C. Liu, H. Li, H. Yao, X. Xue, J. Liu, Z. Tu * , S. Jiang* . Design, Synthesis, and Biological Evaluation of Novel Histone Deacetylase 1 Inhibitors through click chemistry.  Bioorg. Med. Chem. Lett. 2013 , 23, 3295-3299.

24.    X. Li, Z. Tu, H. Li, C. Liu, Z. Li, Q. Sun, Y. Yao, J. Liu, S. Jiang* .Biological evaluation of new largazole analogues: Alteration of macrocyclic scaffold with Click chemistry; ACS Medicinal Chemistry Letters . 2013 , 4 , 132-136.

25.    Y. Qiu, W. Jia, Z. Yao, F. Wu, S. Jiang *. 2-Carbomethoxy-3-hydroxyquinoxaline-di- N - oxide as a novel ligand for the copper-catalyzed coupling reaction of phenols and aryl halides.  Organic & Biomolecular Chemistry. 2013 , 11, 1502-1510.

26.    Yang, Mei; He, Jiangbo; Cheng, Yongxian; Jiang, Sheng* . Synthesis of 3-[(Z)-pentadec-8-enyl]catechol and its anti-angiogenesis activity. Chinese Journal of Organic Chemistry . 2013 , 33(6), 1319-1325.

27.    D. Che, K. Yang, H. Xiang,S. Jiang* . New ligands for copper-catalyzed CN coupling reactions with aryl halides; Tetrahedron Letters . 2012 , 53, 7121-7124.

28.    Y. Liu, X. Cheng, L. Guo, C. Mao, Y. Chen, H. Liu, Q. Xiao, S. Jiang , Z. Yao, G. Zhou. Identification of an annonaceous acetogenin mimetic, AA005 , as an AMPK activator and autophagy inducer in colon cancer cells; PLoS One . 2012 , 7 , e47049.

29.    K. Su, Y. Qiu,; Y.Yao,; D. Zhang, S. Jiang* . 8-hydroxyquinolin-N-oxide-promoted copper-catalyzed CS cross-coupling of thiols with aryl iodides; Synlett . 2012 , 23, 2853-2857.

30.     Q. Xiao, Y. Liu, Y. Qiu, G. Zhou, C. Mao, Z. Li, Z.-J. Yao * , S. Jiang* . Potent Antitumor Mimetics of Annonaceous Acetogenins Embedded with an Aromatic Moiety in the Left Hydrocarbon Chain Part; J. Med. Chem. 2011 , 54 , 525-533.

31.    K. Yang, Y. Qiu, Z. Li, Z. Wang, S. Jiang* , Ligands for Copper-Catalyzed C-N Bond Forming Reactions with 1 Mol% CuBr as Catalyst.  J. Org. Chem , 2011 , 76, 3151-3159.

32.     Y. Qiu, Y. Liu, K. Yang, W. Hong, Z. Li, Z. Wang, S. Jiang*. New Ligands That Promote Cross-Coupling Reactions between Aryl Halides and Unactivated Arenes.  Org. Letters , 2011 , 13 , 3556-3559 .

33.     K. Yang, Z. Li, Z. Wang, S. Jiang* . Highly Efficient Synthesis of Phenols by Copper-Catalyzed Hydroxylation of Aryl Iodides, Bromides, and Chlorides.  Org. Letters , 2011 , 13, 4340-4343 .

34.     W. Wu, Z. Li, G. Zhou,  S. Jiang* . Total synthesis of argyrins A and E.  Tetrahedron. Lett . 2011 , 52 , 2488-2491.

35.    Z. Yao, X. Zeng, W. Yi,S. Jiang* . Stereoselective Synthesis of (S,E)-2-(trimethylsilyl)ethyl 3-hydroxy-7-(tritylthio) hept-4-enoate. Letters in Organic Chemistry, 2011 , 8 , 66-69.

36.    Q. Xiao, Y. Liu, Y. Qiu, Z. Yao, G. Zhou, Z.-J.Yao* , S. Jiang* . Design, synthesis of symmetrical bivalent mimetics of annonaceous acetogenins and their cytotoxicities.  Bioorg. Med. Chem. Lett. 2011 , 21 , 3613-3615.

37.     S. Li, H. Yao, J. Xu * , S. Jiang* . Synthetic Routes and Biological Evaluation of Largazole and Its Analogues as Potent Histone Deacetylase Inhibitors. Molecules , 2011 , 16 , 4681-4694.

38.    L. Johannessen, J.Remsberg, V. Gaponenko, KM Adams, JJ Barchi, SG Tarasov, S. Jiang ,   NI Tarasova. Peptide Structure Stabilization by Membrane Anchoring and its General Applicability to the Development of Potent Cell-Permeable Inhibitors. ChemBioChem. 2011 , 12 , 914- 921.

39.     Z. Yao, Y. Xu, M. Zhang, S. Jiang , MC Nicklaus, C. Liao. Discovery of a novel hybrid from finasteride and episteride as5a-reductase inhibitor.  Bioorg. Med. Chem. Lett, 2011 , 21 , 475-478.

40.    W. Hong, Y. Qiu, Z. Yao, Z. Wang,S. Jiang* . Palladium-Catalyzed Direct C–H Arylation of Unactivated Arenes with Aryl Halides.  Tetrahedron. Lett . 2011 , 52, 4916-4919.

41.    X. Zeng, W. Huang, Y. Qiu, S. Jiang *. Efficient Copper-Catalyzed Synthesis of Anilines by Employing Aqueous Ammonia.  Organic & Biomolecular Chemistry. 2011 , 9, 8224-8227.

42.    Y. Xu, F. Wu, Z. Yao, S. Jiang . Synthesis of quinoxaline 1,4-di-N-oxide analogues and crystal structure of 2-carbomethoxy-3-hydroxyquinoxaline-di-N-oxide. Molecules , 2011 ,  6894-6901 .

43.     X. Zeng, B. Yin, Z. Hu, C. Liao, Z. Li, G. Zhou*, S. Jiang * .Total Synthesis and Biological Evaluation of Largazole and Derivatives with Promising Selectivity for Cancers Cells.  Orgainc. Lett . 2010 , 12 , 1368-1371.

44.     J. Zheng, B. Yin, W. Huang, X. Li, H. Yao, Z. Liu, S. Jiang *. Efficient and selective cleavage of the t -butoxycarbonyl group from di- t -butylimidodicarbonate using catalytic bismuth (III) bromide in acetonitrile. Tetrahedron. Lett . 2009 , 50 , 5094-5097.

45.     S. Jiang* C. Liao, L. Bindu, B. Yin, KW Worthy, RJ Fisher, TR Burke, Jr., MC Nicklaus, PP Roller. Discovery of thioether-bridged cyclic pentapeptides binding to Grb2-SH2 domain with high affinity. Bioorg. Med. Chem. Lett.2009 , 19 , 2693-2698.

46.    Z. Nikolovska-Coleska, J. Meagher, S. Jiang,  C. Yang, S. Qiu, PP Roller, J. Stuckey, S. Wang. Interaction of a Cyclic, Bivalent Smac Mimetic with the X-Linked Inhibitor of Apoptosis Protein. Biochemistry . 2008 , 47 , 9811-9824.

47.     S. Jiang *, Z. Li, K. Ding, PP Roller. Recent Progress of Synthetic Studies to Peptide and Peptidomimetic Cyclization. Current Organic Chemistry. 2008 , 12 , 1502-1542.

48.     Z. Nikolovska-Coleska, J. Meagher, S. Jiang, SA Kawamoto, W. Gao, H. Yi, D. Qin, PP Roller, J. Stuckey, S. Wang. Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains. Anal Biochem. 2008 374 , 87-98.

49.     OA Timofeeva, V. Gaponenko, SJ Lockett, SG Tarasov, S. Jiang , CJ Michejda, AO Perantoni, NI Tarasova. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target.  ACS Chem Biol. 2007 , 2 , 799-809.

50.     S. Jiang, P. Li, SL Lee, CY Lin, YQ Long, MD Johnson, RB Dickson, PP Roller. Design and Synthesis of redox stable analogues of Sunflower Trypsin inhibitors (SFTI-1) on solid support, potent inhibitors of Matriptase. Orgainc. Lett . 2007 9 , 9-12 .

51.    HX. Liu, GR. Huang, HM Zhang, S. Jiang, J.-R. Wu, Z. -J. Yao.  A Structure-Activity Guided Strategy for Fluorescent Labeling of Annonaceous Acetogenin Mimetics and their Application in Cell Biology .ChemBioChem.2007 8 , 172-177.

52.     P. Li,  S. Jiang,  SL Lee, CY Lin, MD Johnson, CJ Michejda, RB Dickson, PP Roller.Synthesis and evaluation of analogs of SFTI-1, potent inhibitors of the Type II transmembrane serine protease, Matriptase. J. Med. Chem. 2007 , 50, 5976-5983.

53.    P. Li, S. Jiang,  PCStephanie, O. Lyn, DN Krag,PP Roller. Design and Synthesis of Water-Soluble Conjugates of Paclitaxel to Extracellular Doma in of ErbB2-Recognizing Peptide. Biopolymers. 2007 , 87,  225 -230.

54.    H. Sun, Z. Nikolovska-Coleska, J. Lu, J. Meagher, C. Yang, S. Qiu, Y. Tomita, Y. Ueda, S. Jiang,  Krajewski, PP Roller, JA Stuckey, S.Wang.Design, Synthesis and Characterization of A Potent, Non-Peptide, Cell-Permeable, Bivalent Smac Mimetic that Concurrently Targets both the BIR2 and BIR3 Domainsin XIAP. J. Am. Chem. Soc. 2007 , 129, 15279-15294. 

55.    GZ Tang, CY Yang, Z. Nikolovska-Coleska, J. Guo, S. Qiu, RX Wang, W. Gao, GP Wang, J. Stuckey, K. Krajewski, S. Jiang,  PP Roller, S. Wang .Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins.  J. Med. Chem.2007 , 50, 1723-1726.

56.    GZ Tang, K. Ding, Z. Nikolovska-Coleska, CY Yang, S. Qiu, S. Shangary, RX Wang, J. Guo, W. Gao, J. Meaghe, J. Stuckey, K. Krajewski, S . Jiang,  PP Roller, S. Wang.Structure-Based Design of Flavonoid Compounds As a New Class of Small-Molecule Inhibitors of the Anti-apoptotic Bcl-2 Proteins. J. Med. Chem.2007 50 , 3163-3166.

57.    J. Chen, Z. Nikolovska-Coleska, CY Yang, C. Gomez, W. Gao, K. Krajewski, S. Jiang , P.  P. Roller, S. Wang. Design and synthesis of a new, conformationally constrained , macrocyclic small-molecule inhibitor of STAT3 via 'click chemistry'.Bioorg. Med. Chem. Lett.2007 17 , 3939-3942.

58.     S. Jiang,  P. Li, CC Lai, JA Kelley,P. Roller.Design and Practical Synthesis of Fully Protected analogs of L-γ-Carboxyglutamic Acid.  J. Org. Chem. 2006 , 71 , 7307-7314.

59.     S. Jiang,  P. Li, M. Peach, RJ Fisher, TR Burke, M. Nicklaus, PP Roller. Structure-based design of potent Grb2-SH2 domain antagonists not relying on phosphotyrosine mimics.  Biochem. Biophys. Res. Commun. 2006 , 349 , 497-503.

60.     S. Jiang,  CC Lai, JA Kelley, PP Roller. A   Practical Synthesis of Fully Protected L-γ-Carboxyglutamic Acid (L-Gla).  Tetrahedron. Lett . 2006 , 47, 23-25.

61.    GP Wang,  Z. Nikolovska-Coleska, CY Yang, RX Wang, GZ Tang, J. Guo, S.    Shanggary, S. Qiu, W. Gao, DJ Yang, J. Meagher, J. Stuckey, K. Krajewski , S. Jiang,  PP Roller, HO Abbaan, Y. Tomita, S. Wang. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.  J. Med. Chem.2006 , 49, 6139-6142.

62.    Y. Zhao, S. Jiang,  YW Guo, Z.-J.Yao Synthesis of two naturally occurring 4-hydroxylated butenolides with PTP1B inhibitory activity. Chinese. J. Chem 2005 , 23 , 173-175.

63.     S. Jiang , Y. Li, XG Chen, TS Hu, YL Wu, Z.-J. Yao. Parallel fragment assembly strategy towards multiple-ether mimicry of anticancer annonaceous acetogenins.  Angew. Chem. Int. Ed . 2004 , 43 , 329-334. 

64.    GR Huang, S. Jiang , YL Wu, ZJ Yao, JR Wu. Induction of cell death of gastric cancer cells by a modified compound of the annonaceous acetogenin family.  Chem BioChem 2003 , 4 , 1216-1221.

65.    BB Zeng, YK Wu, S. Jiang , Q. Yu, ZJ Yao, Z. Liu, H. Li, Y. Li, X. Chen, YL Wu. Studies on Mimicry of Naturally occuring Annonaceous Acetogenins: Non-THF Analogues Leading to Remarkable Selective Cytotoxicity Against Human Tumor cells.Chem. Eur. J. 2003 ,  9 , 282-290.

66.     S. Jiang , YL Wu, ZJ Yao. Synthesis of A Mimicking Hybrid of Annonaceous acetogenin with Steroid for considerable Antitumor Activity Investigation.Chinese J. Chem. 2002 20 , 1393-1400.

67.     S. Jiang , YL Wu, ZJ Yao.  First Synthesis of Mosquito larvicidal Butenolides I and II.  Chinese J. Chem. 2002 20 , 692-696.

68.        S. Jiang , Z. Liu, G. Sheng, BB Zeng, XG Cheng, YL Wu, ZJ Yao. Mimicking of Annonaceous Acetogenins: Enantionselective Synthesis of a (4R)-Hydroxy Analog Having Potent Antitumor Activity.  J. Org. Chem , 2002 , 67 , 3404-3408.


Jiang Shengnan Han doctoral supervisor Guangzhou Institute of Biomedicine and Health
Email: jiang_sheng@gibh.ac.cn
Tel: 020-32015318
Mobile number:
Mailing address: No. 190 Kaiyuan Avenue, Luogang District, Guangzhou
Postcode : 510530

Research areas

1. Rational design, synthesis and structure-activity relationship research of active small molecules and polypeptide compounds targeting specific pathogenic genes.
2. Total synthesis of natural products with antitumor activity and discovery of new leading drugs.

Admissions Information

   
Admissions Major
100701 - Medicinal Chemistry
Admissions direction
Design and Synthesis of
Anticancer Drugs Design and Synthesis of Anticancer Drugs

Education background

   
Education
-- Postgraduate
Bachelor of Science
-- PhD
study abroad
2003, 11~ 2007, 11 National Cancer Institute, National Institutes of Health (NIH, NCI), Postdoctoral fellow

work experience

2007, 11 ~ present, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences

Publication information

   
Published papers
(1) Total synthesis of argyrins A and E, Tetrahedron. Lett., 2011, corresponding author
(2) Design, synthesis of symmetrical bivalent mimetics of annonaceous acetogenins and their cytotoxicities, Bioorg. Med. Chem. Lett., 2011, corresponding author
(3) Potent Antitumor Mimetics of Annonaceous Acetogenins Embedded with an Aromatic Moiety in the Left Hydrocarbon Chain Part, J. Med. Chem, 2011, corresponding author
(4) Ligands for Copper Catalyzed CN Bond Forming Reactions with CuBr as Catalyst, J. Org Chem, 2011, corresponding author
(5) Synthetic Routes and Biological Evaluation of Largazole and Its Analogues as Potent Histone Deacetylase Inhibitors, Molecules, 2011, corresponding author
(6) New Ligands That Promote Cross-Coupling Reactions between Aryl Halides and Unactivated Arenes, Org. Letters, 2011, corresponding author
(7) Total Synthesis and Biological Evaluation of Largazole and Derivatives with Promising Selectivity for Cancers Cells, Organicc. Lett., 2010, corresponding author

Research activities

   
scientific research projects
Presided over the National Natural Science Foundation of China, the 973 sub-project, and the National New Drug Creation Major Project.

guide students

Currently guiding students

Xiao Qicai Master student 077901-Medicinal chemistry  

Wu Wenbin Postgraduate 077901-Medicinal Chemistry  

Liu Yanghan Postgraduate 077901-Medicinal Chemistry  

Ad1